BDRX

Biodexa Pharmaceuticals Plc ADR

2.48

Nov 06 • 3:47 PM ET +0.07 (2.88%)

2.50

Aftermarket • 7:59 PM ET +0.02 (0.83%)

Healthcare Biotechnology United Kingdom Nano NASD

Peers: KZIA NTHI MBRX NCNA PPBT LTRN CDT SCNI QNRX XTLB

Scroll to Statements

Index	-
Market Cap	1.29M
Enterprise Value	-3.00M
Income	-5.93M
Sales	0.00M
Book/sh	0.00
Cash/sh	8.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Dec 07, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1952.36
P/C	0.30
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.41
Current Ratio	2.41
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-53.56
EPS next Y	0.00
EPS next Q	0.00
EPS this Y	100.00%
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	95.64% 89.65%
Sales past 3/5Y	- -
EPS Y/Y TTM	97.97%
Sales Y/Y TTM	-
EPS Q/Q	100.00%
Sales Q/Q	-
Earnings	Sep 11 AMC
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	0.66%
Inst Trans	-
ROA	-31.88%
ROE	-41.72%
ROIC	-46.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-24.18%
SMA50	-50.01%
SMA200	-89.34%
Trades

Shs Outstand	932.64M
Shs Float	-
Short Float	-
Short Ratio	0.19
Short Interest	0.11M
52W High	357.60 -99.31%
52W Low	2.41 2.88%
Volatility	14.48% 15.69%
ATR (14)	0.57
RSI (14)	33.23
Beta	1.29
Rel Volume	0.02
Avg Volume	610.46K
Volume	13,250

Perf Week	-27.71%
Perf Month	-40.82%
Perf Quarter	-80.63%
Perf Half Y	-92.71%
Perf YTD	-97.27%
Perf Year	-98.83%
Perf 3Y	-99.99%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	1.00
Target Price	72.00
Prev Close	2.41
Price	2.48
Change %	2.88%

Consensus

Strong Buy

Avg. Price Target

$72.00

Implied Upside

+2,803.8%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Feb 08, 2024	Initiated	LLadenburg Thalmann	Buy	$8	+222.6%

Oct-13-26 09:51AM	Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates (InvestorsHub) -8.61%
08:30AM	Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP (GlobeNewswire)
Sep-23-26 06:30AM	The Longview: Fireside Chat with Biodexa CEO Stephen Stamp (ACCESSWIRE)
Sep-15-26 08:00AM	Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds (GlobeNewswire) +18.75%
Sep-11-26 04:30PM	Interim results for the six months ended June 30, 2026 (GlobeNewswire) +96.94% -13.85%
08:30AM	Loading…
Aug-19-26 08:30AM	Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP (GlobeNewswire) -9.35%
Jul-29-26 04:30PM	Result of General Meeting (GlobeNewswire)
08:30AM	Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France (GlobeNewswire)
Jun-30-26 04:30PM	Result of Annual General Meeting (GlobeNewswire)
08:00AM	Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants (GlobeNewswire)
Jun-29-26 08:30AM	Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress (GlobeNewswire)
Jun-17-26 04:30PM	Postponement and Re-scheduling of Annual General Meeting (GlobeNewswire)
May-14-26 08:30AM	Biodexa issues letter to Shareholders (GlobeNewswire) -8.48%
Apr-02-26 08:30AM	Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies (GlobeNewswire) +42.23%
Mar-27-26 05:00PM	Preliminary Results for the Year Ended 31 December 2025 (GlobeNewswire) -6.50%
08:30AM	Loading…
Mar-23-26 08:30AM	Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group (GlobeNewswire)
Mar-18-26 05:00PM	ADR Ratio Change (GlobeNewswire) -10.92%
Mar-09-26 08:30AM	Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients (GlobeNewswire)
Feb-19-26 07:30AM	Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer (ACCESSWIRE)
Feb-04-26 08:30AM	Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST (GlobeNewswire) -11.04%
Jan-06-26 08:41AM	Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary (TipRanks)
Jan-05-26 08:30AM	Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary (GlobeNewswire)
Dec-18-25 08:30AM	Biodexa Announces Pricing of $10 Million Public Offering (GlobeNewswire) -23.99%
Dec-01-25 08:30AM	Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP (GlobeNewswire)
Nov-24-25 08:30AM	Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP (GlobeNewswire)
Nov-03-25 08:30AM	Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion (GlobeNewswire)
Oct-06-25 08:30AM	Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA - IGC Conference on October 11, 2025 (GlobeNewswire)
Sep-12-25 08:30AM	Interim results for the six months ended June 30, 2025 (GlobeNewswire)
Sep-08-25 07:00AM	Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled (ACCESSWIRE) -5.84%
Sep-03-25 12:00PM	Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +6.16%
06:40AM	Loading…
Aug-19-25 06:40AM	First two subjects enrolled in Biodexas Phase III trial for FAP treatment (Clinical Trials Arena) -5.11%
Aug-18-25 08:30AM	Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Jul-31-25 09:30AM	ADR Ratio Change Effective (GlobeNewswire) -9.11%
Jul-28-25 07:00AM	How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market (ACCESSWIRE)
Jul-15-25 04:30PM	ADR Ratio Change (GlobeNewswire) -10.21%
Jul-14-25 08:30AM	Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) (GlobeNewswire) +12.13%
Jun-27-25 08:30AM	Results of Annual General Meeting (GlobeNewswire) -6.21%
Jun-25-25 08:30AM	Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Jun-23-25 08:30AM	Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) (GlobeNewswire) +6.22%
Jun-18-25 07:00AM	Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study (ACCESSWIRE) +29.35%
Jun-11-25 04:30PM	Result of General Meeting (GlobeNewswire)
Jun-04-25 08:30AM	Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes (GlobeNewswire)
May-31-25 08:40AM	Biodexa Pharmaceuticals sees cash runway into 1Q26 (TipRanks)
May-30-25 08:30AM	Shareholder Update (GlobeNewswire)
May-22-25 04:30PM	Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting (GlobeNewswire) +6.92% -17.27%
08:30AM	Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M (GlobeNewswire)
May-20-25 09:55AM	Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-12-25 08:30AM	Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP (GlobeNewswire) -12.77%
May-02-25 04:30PM	Result of General Meeting (GlobeNewswire)
Apr-24-25 12:00PM	What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock (Zacks) +9.86%
Apr-17-25 08:30AM	Notice of General Meeting (GlobeNewswire)
Apr-11-25 08:30AM	Preliminary Results for the Year Ended 31 December 2024 (GlobeNewswire) +12.74%
Mar-19-25 07:00AM	With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter (ACCESSWIRE) +16.13%
Mar-10-25 08:30AM	Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP (GlobeNewswire) -6.56%
Mar-06-25 08:30AM	Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP (GlobeNewswire)
Feb-24-25 08:30AM	Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-13-25 08:30AM	Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 (GlobeNewswire)
Feb-12-25 07:30AM	Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status (ACCESSWIRE)
Feb-10-25 08:30AM	Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis (GlobeNewswire) +31.94%
Jan-22-25 08:30AM	Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer (GlobeNewswire) -5.45%
Nov-22-24 08:30AM	Result of General Meeting (GlobeNewswire)
Nov-21-24 07:35AM	Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic (ACCESSWIRE) +14.29%
Nov-12-24 08:48AM	Biodexa Pharmaceuticals PLC ( Biodexa or the Company ) Regains Compliance For Continued Listing on Nasdaq (GlobeNewswire)
Nov-07-24 04:30PM	Notice of General Meeting (GlobeNewswire) -5.42%
Oct-17-24 07:30AM	Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer (ACCESSWIRE) -30.12%
Oct-15-24 04:15PM	Biodexa Announces Successful Appeal of Nasdaq Delisting (GlobeNewswire) +67.66%
Oct-04-24 08:30AM	Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma (GlobeNewswire) -7.62%
Sep-26-24 08:30AM	Interim results for the six months ended June 30, 2024 (GlobeNewswire)
Sep-19-24 04:30PM	ADR Ratio Change (GlobeNewswire) -20.19%
Sep-16-24 08:30AM	Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant (GlobeNewswire)
Aug-30-24 04:30PM	Receipt of Nasdaq Delisting Determination - Plans to Appeal (GlobeNewswire) -17.25%
Jul-23-24 08:30AM	Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Jul-19-24 08:30AM	Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -14.94%
Jul-16-24 08:30AM	Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada (GlobeNewswire)
Jul-12-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 12:51PM	JOBY Stock Pops After Completing 523-Mile eVTOL Flight (InvestorPlace) +51.88%
12:31PM	KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains (InvestorPlace)
12:10PM	Why Is Biodexa Pharmaceuticals (BDRX) Up 56% Today? (InvestorPlace)
08:30AM	Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data (ACCESSWIRE)
Jul-02-24 08:30AM	Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 (GlobeNewswire)
Jun-24-24 08:30AM	Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa at 12 months in Familial Adenomatous Polyposis (FAP) (GlobeNewswire) -15.63%
Jun-13-24 09:35AM	Results of Annual General Meeting (GlobeNewswire)
Jun-10-24 08:30AM	Twelve month Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona (GlobeNewswire)
Jun-03-24 08:00AM	Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer (ACCESSWIRE) +10.95%
May-22-24 08:30AM	Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises (GlobeNewswire) -45.06%
May-21-24 08:30AM	Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting (GlobeNewswire) +83.46%
08:28AM	Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today? (InvestorPlace)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-15-24 03:58AM	Posting of Annual Report & Notice of AGM - Total Voting Rights (GlobeNewswire)
May-09-24 08:00AM	Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition (ACCESSWIRE)
Apr-30-24 11:52AM	Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting (GlobeNewswire) +15.27%
Apr-28-24 12:01PM	12 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-26-24 03:18PM	Why Is Biodexa (BDRX) Up 70% Today? (InvestorPlace) +79.36%
08:30AM	Biodexa Enters Into Exclusive License to eRapa , a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Apr-19-24 08:00AM	Preliminary Results for the Year Ended 31 December 2023 (GlobeNewswire) -8.30%
Mar-28-24 11:22AM	Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today? (InvestorPlace) +88.59%
08:15AM	Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers (ACCESSWIRE)
Mar-01-24 08:00AM	Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone (ACCESSWIRE) +7.09%
Feb-23-24 08:30AM	Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update (GlobeNewswire)

Show Previous News

Biodexa Pharmaceuticals Plc is a drug delivery technology company. The firm is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. Its proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

CEO & DirectorMr. Stephen Anthony Stamp

Company SecretaryMs. Fiona Mary Sharp

Ph.D.Dr. Daniel Palmer MBA

Chief Business OfficerMr. Steve Ellul

FACOGDr. Gary A. Shangold CPI

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BDRX

Biodexa Pharmaceuticals Plc ADR

Upgrade your Finviz experience